Wednesday, July 8, 2026

pharma · EBV-induced Lymphomas · Coronary Artery Disease

Evidence Based Cataract

Evidence Based Cataract is a pharma organization headquartered in THOUSAND OAKS, CA, CN. Primary therapeutic focus areas include EBV-induced Lymphomas, Coronary Artery Disease, Primary Progressive Multiple Sclerosis, Lup

THOUSAND OAKS, CA, CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
THOUSAND OAKS, CA, CN
Programs
10
Drugs
8
Patents
10
Clinical program

CMV-pp65 CTLs

Phase 2 · mab · Cytomegalovirus

CMV-pp65 CTLs for Cytomegalovirus is a Phase 2 program (mab) at Evidence Based Cataract Study Group with 1 ClinicalTrials.gov record(s).

Internal code 12-086

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Evidence Based Cataract Study Group
Phase
Phase 2
Modality
mab
Indication
Cytomegalovirus
Status
completed
Trials
1

Clinical trials